Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lauren R. Skeffington"'
Autor:
Luigi D. Notarangelo, Alexandra F. Freeman, Jennifer S. Wilder, Veena Kapoor, Irini Sereti, Jeffrey I. Cohen, Harry L. Malech, Ronald E. Gress, Jennifer L. Sadler, Jennifer A. Kanakry, Ellen Carroll, Miranda M. Broadney, Jeremy J. Rose, Lauren R. Skeffington, Elizabeth Garabedian, Xiao-Yi Yan, Natalia S. Nunes, Amy P. Hsu, Seth M. Steinberg, Christopher G. Kanakry, Gulbu Uzel, Rochelle Fletcher, Steven M. Holland, Andrea Lisco, William G. Telford, Juan Gea-Banacloche, Nirali N. Shah, Mark Parta, Christa S. Zerbe, Daniel H. Fowler, Stephanie N. Hicks, Dimana Dimitrova, Thomas E. Hughes, Jenny E Blau
Publikováno v:
Biol Blood Marrow Transplant
Allogeneic blood or marrow transplantation (BMT) is a potentially curative therapy for patients with primary immunodeficiency (PID). Safe and effective reduced-intensity conditioning (RIC) approaches that are associated with low toxicity, use alterna
Autor:
Stephanie N. Hicks, Scott Napier, Dimana Dimitrova, Vladimir A. Valera Romero, Juan Gea-Banacloche, Ellen Carroll, Anita Stokes, Mark Parta, Jennifer A. Kanakry, Jennifer L. Sadler, Seth M. Steinberg, Lauren R. Skeffington, Christopher G. Kanakry, Ronald E. Gress, Gary A. Fahle
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S322-S323
Allogeneic HCT recipients may develop BK virus (BKV)-associated hemorrhagic cystitis (BKV-HC), typically early after engraftment. Yet, BKV levels in urine and blood are not routinely monitored pre- or post-HCT. Among HCT recipients with primary immun
Autor:
Elizabeth M. Kang, Theresa Jerussi, Nirali N. Shah, Minoo Battiwalla, A. John Barrett, Ronald E. Gress, Matthew M. Hsieh, Ricardo J. Melendez-Munoz, Steven Z. Pavletic, Daniel H. Fowler, Rachel Marchalik, Jennifer A. Kanakry, Lauren R. Skeffington, Elizabeth M. Hellewell, Jennifer Wilder, Megan Kenyon, Courtney D. Fitzhugh, Sawa Ito, Dimana Dimitrova
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S353-S354
Latent EBV infection can lead to EBV-PTLD when proliferating, EBV+ B cells are insufficiently controlled by cellular immunity. At the National Institutes of Health (NIH), all HCT recipients are monitored weekly from day 0-100 with whole blood EBV qPC
Autor:
Stephanie Cotton, Jeffrey I. Cohen, Steven Z. Pavletic, Steven M. Holland, Alexandra F. Freeman, Lauren M. Curtis, Christa S. Zerbe, Lauren R. Skeffington, Jennifer A. Kanakry, Christopher G. Kanakry, V. Koneti Rao, Gulbu Uzel, Jennifer Mann, Ronald E. Gress, Daniel H. Fowler, Juan Gea-Banacloche, Dimana Dimitrova
Publikováno v:
Biology of Blood and Marrow Transplantation. 23:S266-S267
Antibody conjugates have broad utility in basic, preclinical, and clinical applications. Conventional antibody conjugation through the amine group of lysine or the thiol group of cysteine residues yields heterogeneous products of undefined stoichiome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad32075344491e9d76b3dc4e97e11028
https://europepmc.org/articles/PMC2825887/
https://europepmc.org/articles/PMC2825887/